AcelRx Pharmaceuticals Inc Investor Relations Material
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The Company's lead product candidate is DSUVIA™ (sufentanil sublingual tablet, 30 mcg) which has completed Phase 3 trials. The Company believes that DSUVIA is a potential first-in-class non-invasive treatment option that can deliver rapid relief to patients suffering from moderate to severe acute pain
Upcoming events for
Q4 20222023-03-13
Latest company events
Ticker symbol
ACRX
Country
United States of America
About the company
Investor Relations Page
Dig deeper into the AcelRx Pharmaceuticals Inc fundamentals on Quartr.
- Conference calls from all over the world
- Search for anything across all transcripts
- Consensus estimates
- Comprehensive financial data
- Read the transcripts or scroll the deck
- Slide decks and earnings reports
